TY - JOUR
T1 - Factor XI inhibition in hemodialysis patients
T2 - the safer anticoagulation?
AU - Stamellou, Eleni
AU - Noels, Heidi
AU - Floege, Jürgen
N1 - Funding Information:
Funding : This work was funded by the Deutsche Forschungsgemeinschaft (DFG, German Research Foundation) \u2013 TRR 219 \u2013 Project-ID 322900939, project C1 and M5.
Publisher Copyright:
© 2024 International Society of Nephrology
PY - 2024/7/1
Y1 - 2024/7/1
N2 - Chronic hemodialysis patients exhibit an excessive cardiovascular risk and a marked increase in both thromboembolism and bleeding episodes. Factor XI inhibition may provide anticoagulation, with a low risk of bleeding, and several factor XI inhibitors, including fesomersen, an antisense oligonucleotide, are under development. Recently, a phase 2 study of fesomersen showed a good safety profile in chronic hemodialysis patients and suggested that clotting rates of the arteriovenous fistula and the dialysis circuit are lower.
AB - Chronic hemodialysis patients exhibit an excessive cardiovascular risk and a marked increase in both thromboembolism and bleeding episodes. Factor XI inhibition may provide anticoagulation, with a low risk of bleeding, and several factor XI inhibitors, including fesomersen, an antisense oligonucleotide, are under development. Recently, a phase 2 study of fesomersen showed a good safety profile in chronic hemodialysis patients and suggested that clotting rates of the arteriovenous fistula and the dialysis circuit are lower.
U2 - 10.1016/j.kint.2024.03.029
DO - 10.1016/j.kint.2024.03.029
M3 - Comment/Letter to the editor
SN - 0085-2538
VL - 106
SP - 21
EP - 23
JO - Kidney International
JF - Kidney International
IS - 1
ER -